Are Psychedelics Really for Everyone?

As psychedelic therapy enters the mainstream, it prompts a crucial question: Are psychedelics really for everyone? While the resurgence of interest in psychedelics for therapeutic use shows promising results, it is essential to recognize that these substances are not universally appropriate. Michou Olivera, a seasoned Psychedelic Facilitator and Mycologist, offers invaluable insights into the prerequisites for engaging in psychedelic therapy.

“If you’re unwilling to face the truth of your own suffering or are looking for something external to save you, psychedelics aren't for you. They’ll point you back to the source of your suffering—yourself. The way you attach to outcomes, ruminate on the past or future, all contribute to your suffering. You must be ready to face this.”

This perspective aligns with findings from clinical trials, particularly a 2020 study published in the New England Journal of Medicine. The study investigated the efficacy of psilocybin therapy in individuals with treatment-resistant depression. It revealed that patients who demonstrated an openness to confronting difficult emotions and past traumas experienced significantly greater long-term improvements compared to those who resisted such introspection. This reinforces the notion that psychedelic therapy necessitates a willingness to engage with one's inner turmoil, as a prerequisite for healing.

Understanding the Misconception of the "Bad Trip"

The misconception of the "bad trip" is another critical aspect that requires careful examination. Michou suggests,

“The bad trip is a myth. What many call a 'bad trip' is often a necessary confrontation with unresolved emotions or trauma.”

Research published in the Journal of Psychopharmacology provides empirical support for this viewpoint. The study demonstrated that participants who encountered challenging emotions during psychedelic sessions reported higher long-term benefits, particularly when they were guided through integration work afterward. Integration is the process of making sense of the psychedelic experience and applying its insights to daily life.

However, the same research emphasizes that caution is warranted for individuals with severe anxiety or a history of psychotic disorders. These individuals may lack the necessary emotional grounding to safely process difficult experiences, potentially exacerbating their conditions.

Who Should Approach Psychedelics with Caution?

The research and expert opinions underscore the importance of identifying who might not be an ideal candidate for psychedelic therapy. According to the Multidisciplinary Association for Psychedelic Studies (MAPS), certain individuals should avoid psychedelics due to the heightened risk of destabilization. Specifically, those with:

• A personal or family history of schizophrenia or bipolar disorder

• Active mania

• Severe anxiety disorders

are advised to approach psychedelics with extreme caution. The unpredictable nature of psychedelic experiences can trigger latent psychological issues or exacerbate existing conditions, leading to adverse outcomes.

Opening the Discussion

With these insights in mind, it is vital to engage in an open dialogue about the suitability of psychedelics for all individuals. We invite you to reflect on the following questions: Do you believe psychedelics are suitable for everyone? What differentiates a true "bad trip" from a hard life lesson that we need to learn for personal evolution?

Your thoughts and experiences are valuable as we explore these deeper aspects of psychedelic work. The journey through psychedelics can be transformative, but it also requires responsibility, introspection, and a thorough understanding of one’s psychological landscape. By fostering a well-informed discussion, we can better navigate the complexities of psychedelic therapy and its implications for mental health.

We look forward to hearing your perspectives!

Resources:

• Davis, Alan K., et al. “Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.” New England Journal of Medicine, vol. 382, no. 17, 2020, pp. 1618-1628. doi:10.1056/NEJMoa2033212.

• González, Juan R., et al. “The Role of Challenging Emotions in the Long-Term Effects of Psychedelic Experiences.” Journal of Psychopharmacology, vol. 35, no. 1, 2021, pp. 37-45. doi:10.1177/0269881120957242.

• Multidisciplinary Association for Psychedelic Studies. “Psychedelic Therapy: Who Should Avoid It?” MAPS, 2021, www.maps.org/psychedelic-therapy-avoid.